Summary
Epcoritamab is an investigational immunotherapy drug being developed for the treatment of follicular lymphoma. In this study, participants will be randomly allocated to one of three treatment arms. Around 500 adult participants will be enrolled in approximately 300 sites across the world. Treatment cycles are 28 days in length.
In Experimental Arm A, participants will receive Epcoritamab at dose level A, which will be given as an injection under the skin, in combination oral Lenalidomide and an IV infusion of Rituximab for 12 cycles.
In Experimental Arm B, participants will receive Epcoritamab at dose level B, which will be given as an injection under the skin, in combination with oral Lenalidomide and an IV infusion as Rituximab for 12 cycles. Enrollment for this arm has now closed.
In the Active Comparator Arm, participants will receive oral Lenalidomide and an IV infusion of Rituximab for 12 cycles.
Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.